Health Care • Biotechnology: Laboratory Analytical Instruments
$1.20 ▼ +0.00
(-0.41%)
MKT CAP: $16.8M • VOL: 67.2K
52W L $1 52W H $2
ROARABLE / RQD
D- • 36/100
PIOTROSKI
4 / 9
BNGO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $28.5M | $30.8M | $36.1M |
| YoY Revenue Growth % | -7.4% | -14.8% | — |
| Gross Profit | $13.2M | $380.0K | — |
| Gross Margin % | 46.3% | 1.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$33.3M | -$104.0M | -$215.2M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$26.4M | -$112.0M | -$232.5M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$16.3M | -$68.9M | -$125.2M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$16.3M | -$68.9M | -$125.2M |
| FCF Margin % | -57.3% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $3.0M | $9.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $44.4M | $35.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BNGO.